Holen Sie sich die Stockscreener-App
37.06
0.96%
-0.36
Handel nachbörslich:
37.06
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. Stock (NL0012169213): Sector Check On Diagnostics Player - AD HOC NEWS
Qiagen N.V. Stock: In focus after the latest verified market update - AD HOC NEWS
A Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75 - GuruFocus
Qiagen N.V. stock (NL0012169213): focus on molecular diagnostics and steady demand drivers - AD HOC NEWS
Former AdvaMedDx Board Chair Joins Bruker’s Governing Body - Medical Product Outsourcing
Qiagen N.V. stock (NL0012169213): Diagnostics player stays in focus after latest quarterly update - AD HOC NEWS
How Qiagen N.v. (QGEN) Affects Rotational Strategy Timing - Stock Traders Daily
Qiagen N.V. stock (NL0012169213): Diagnostic specialist updates investors after recent earnings - AD HOC NEWS
Evaluating Qiagen (NYSE:QGEN) After New Bundibugyo Ebolavirus Digital PCR Assays Catch Investor Attention - Sahm
Qiagen N.V. Common Shares (NY: QGEN - FinancialContent
Goldman Sachs Discloses 3.14% Voting Stake in QIAGEN - TipRanks
UBS reveals 3.04% voting stake in Qiagen after AFM filing - TipRanks
Qiagen reports 2.75% voting stake in its shares held by UBS Group - TipRanks
MFS reports 12.45M-share, 6.0% stake in QGEN (NYSE: QGEN) - Stock Titan
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QIAGEN Business Breakdown and Growth Drivers for 2026 - qz.com
Is Qiagen’s New Bundibugyo Assays Strategy Quietly Reframing Its Infectious Disease Tools Story (QGEN)? - Sahm
Is It Too Late to Buy Qiagen NV (QGEN) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
AlphaValue/Baader Europe Cuts Qiagen Price Target, Estimates Post FY26 Guidance Change - 富途牛牛
LVIP MFS International Growth Fund's Qiagen NV(LTS:0RLT) Holding History - GuruFocus
Qiagen N.V. stock (NL0012169213): Legal probe and Jefferies conference keep shares in focus - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Shares in focus after Jefferies conference appearance and law firm - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V.QGEN - Hastings Tribune
Qiagen N.V. stock (NL0012169213): Deutsche Bank reiterates Buy rating with USD 43 target - AD HOC NEWS
Qiagen (QGEN) Q1 2026 Earnings Transcript - AOL.com
QIAGEN NV : Deutsche Bank keeps its Buy rating - marketscreener.com
Qiagen N.V. (QGEN) Presents at Deutsche Bank German Corporate ConferenceSlideshow (NYSE:QGEN) 2026-06-01 - Seeking Alpha
Evaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price Recovery - Yahoo Finance
Qiagen N.V. (QGEN) Stock Analysis: Healthcare Innovator With Nearly 20% Upside Potential - DirectorsTalk Interviews
Qiagen N.V. stock (NL0012169213): steady after Q1 2026 update while analysts refine outlook - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): shares steady after Q1 2026 update and ownership shift - AD HOC NEWS
UBS Discloses 2.45% Stake in Qiagen via AFM Notification - The Globe and Mail
Bank of America Discloses 3.15% Voting Stake in Qiagen - The Globe and Mail
Legal & General Group Plc Sells 40,221 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock (NL0012169213): UBS stake disclosure and AFM voting rights notice keep insider own - AD HOC NEWS
QIAGEN’s Outlook Reset: Can Digital PCR And Sample Tech Offset QuantiFERON Weakness? - Smartkarma
Qiagen N.V. stock (NL0012169213): New Ebola research assays in focus as valuation metrics come into - AD HOC NEWS
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss? - TradingView
Qiagen N.V. stock (NL0012169213): Diagnostics group under scrutiny after investor investigation upda - AD HOC NEWS
Qiagen NV Bolsters Bundibugyo Ebola Research - Devdiscourse
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak - BioSpace
U.S. Sets Up Ebola Quarantine in Kenya - Devdiscourse
Qiagen N.V. stock (NL0012169213): Diagnostics specialist in focus after latest earnings - AD HOC NEWS
Deutsche Bank Maintains Qiagen NV(QGEN.US) With Buy Rating - 富途牛牛
QIAGEN NV : Buy rating from Deutsche Bank - marketscreener.com
Qiagen N.V. stock (NL0012169213): diagnostics specialist in focus after recent business updates - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Diagnostics player in focus after latest quarterly update - AD HOC NEWS
0.38%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):